A novel series of indazole-/indole-based glucagon receptor antagonists

被引：12

作者：

Lin, Songnian ^{[1
]}

Zhang, Fengqi ^{[1
]}

Jiang, Guoqiang ^{[1
]}

Qureshi, Sajjad A. ^{[1
]}

Yang, Xiaodong ^{[1
]}

Chicchi, Gary G. ^{[1
]}

Tota, Laurie ^{[1
]}

Bansal, Alka ^{[1
]}

Brady, Edward ^{[1
]}

Trujillo, Maria ^{[1
]}

Salituro, Gino ^{[1
]}

Miller, Corey ^{[1
]}

Tata, James R. ^{[1
]}

Zhang, Bei B. ^{[1
]}

Parmee, Emma R. ^{[1
]}

机构：

[1] Merck Res Labs, Early Dev & Discovery Sci & Preclin Dev, Kenilworth, NJ 07033 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 19期

关键词：

Glucagon receptor antagonist; Indazole; Indole; Diabetes; Glucose lowering; HEPATIC GLUCOSE-PRODUCTION; THERAPEUTIC TARGET;

D O I：

10.1016/j.bmcl.2015.08.015

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel, potent series of glucagon receptor antagonists (GRAs) was discovered. These indazole-and indole-based compounds were designed on an earlier pyrazole-based GRA lead MK-0893. Structure-activity relationship (SAR) studies were focused on the C3 and C6 positions of the indazole core, as well as the benzylic position on the N-1 of indazole. Multiple potent GRAs were identified with excellent in vitro profiles and good pharmacokinetics in rat. Among them, GRA 16d was found to be orally active in blunting glucagon induced glucose excursion in an acute glucagon challenge model in glucagon receptor humanized (hGCGR) mice at 1, 3 and 10 mg/kg (mpk), and significantly lowered acute glucose levels in hGCGR ob/ob mice at 3 mpk dose. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：4143 / 4147

页数：5

共 26 条

[1]

Conner S. E., 2010, United States patent, Patent No. [US7816557, 7816557]

[2]

Conner S.E., 2010, US Patent, Patent No. 0324140

[3]

Conner S.E., 2011, US Patent, Patent No. 0124648

[4] THE TRIUMVIRATE - BETA-CELL, MUSCLE, LIVER - A COLLUSION RESPONSIBLE FOR NIDDM [J].

DEFRONZO, RA .

DIABETES, 1988, 37 (06) :667-687

[5] Glucagon Receptor Antagonists for Type II Diabetes [J].

DeMong, Duane E. ;

Miller, Michael W. ;

Lachowicz, Jean E. .

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 43, 2008, 43 :119-137

[6] A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity [J].

Filipski, Kevin J. ;

Bian, Jianwei ;

Ebner, David C. ;

Lee, Esther C. Y. ;

Li, Jian-Cheng ;

Sammons, Matthew F. ;

Wright, Stephen W. ;

Stevens, Benjamin D. ;

Didiuk, Mary T. ;

Tu, Meihua ;

Perreault, Christian ;

Brown, Janice ;

Atkinson, Karen ;

Tan, Beijing ;

Salatto, Christopher T. ;

Litchfield, John ;

Pfefferkorn, Jeffrey A. ;

Guzman-Perez, Angel .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (01) :415-420

[7] Glucagon and regulation of glucose metabolism [J].

Jiang, GQ ;

Zhang, BB .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 284 (04) :E671-E678

[8]

Kelly RP, 2011, DIABETES, V60, pA84

[9] Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor [J].

Kodra, Janos T. ;

Jorgensen, Anker Steen ;

Andersen, Birgitte ;

Behrens, Carsten ;

Brand, Christian Lehn ;

Christensen, Inger Thoger ;

Guldbrandt, Mette ;

Jeppesen, Claus Bekker ;

Knudsen, Lotte B. ;

Madsen, Peter ;

Nishimura, Erica ;

Sams, Christian ;

Sidelmann, Ulla G. ;

Pedersen, Raymon A. ;

Lynn, Francis C. ;

Lau, Jesper .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (17) :5387-5396

[10] Progress towards glucagon receptor antagonist therapy for Type 2 diabetes [J].

Kurukulasuriya, R ;

Link, JT .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (12) :1739-1749

← 1 2 3 →